Banch wrote: ↑Thu May 19, 2022 12:47 am
I recall reviewing at least a couple of articles that indicated that plasmalogens open the blood-brain barrier. In one article, this ability was touted as useful in drug testing.
That's interesting, I've read many articles on factors that open/degrade the blood-brain barrier but don't ever recall plasmalogens being cited among them. In fact, I would think just the opposite seeing as how plasmalogens are a critical component of neuromembranes helping with cellular structure. Can you happen to dig up those articles and share?
I would also be interested in any articles regarding plasmalogens being used to open the BBB for drug testing. I don't recall any articles to that effect either, although nanoparticles
are being thought to be promising for drug delivery, here are a few papers on that:
Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases
Nanoparticles: A Hope for the Treatment of Inflammation in CNS
"Neurodegenerative diseases (NDs) represent a heterogeneous group of aging-related disorders featured by progressive impairment of motor and/or cognitive functions, often accompanied by psychiatric disorders. NDs are denoted as ‘protein misfolding’ diseases or proteinopathies, and are classified according to their known genetic mechanisms and/or the main protein involved in disease onset and progression. Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) are included under this nosographic umbrella, sharing histopathologically salient features, including deposition of insoluble proteins, activation of glial cells, loss of neuronal cells and synaptic connectivity. To date, there are no effective cures or disease-modifying therapies for these NDs. Several compounds have not shown efficacy in clinical trials, since they generally fail to cross the blood-brain barrier (BBB), a tightly packed layer of endothelial cells that greatly limits the brain internalization of endogenous substances. By engineering materials of a size usually within 1–100 nm, nanotechnology offers an alternative approach for promising and innovative therapeutic solutions in NDs. Nanoparticles can cross the BBB and release active molecules at target sites in the brain, minimizing side effects. This review focuses on the state-of-the-art of nanoengineered delivery systems for brain targeting in the treatment of AD, PD and HD."
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders
"Neuroinflammation, an inflammatory response within the central nervous system (CNS), is a main hallmark of common neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), among others. ... . Many drugs have shown promising therapeutic effects on microglia and inflammation. However, the blood–brain barrier (BBB)—a natural barrier preventing brain tissue from contact with harmful plasma components—seriously hinders drug delivery to the microglial cells in CNS. ... Recently, many NPs [nanoparticles] have been reported to be useful vehicles for anti-inflammatory drugs across the BBB to inhibit the over-activation of microglia and neuroinflammation. Therefore, NPs with good biodegradability and biocompatibility have the potential to be developed as an effective and minimally invasive carrier to help other drugs cross the BBB or as a therapeutic agent for the treatment of neuroinflammation-mediated neurodegenerative diseases. In this review, we summarized various nanoparticles applied in CNS, and their mechanisms and effects in the modulation of inflammation responses in neurodegenerative diseases, providing insights and suggestions for the use of NPs in the treatment of neuroinflammation-related neurodegenerative diseases."
“In this article, insights into common neurological disorders and challenges of delivering CNS [Central Nervous System] drugs due to the presence of BBB is provided, before an in-depth review of nanoparticle-based theranostic strategies.”